NASDAQ:ESTAEstablishment Labs Stock Price, Forecast & News

Establishment Labs' stock was trading at $15.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ESTA shares have increased by 17.5% and is now trading at $17.80.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Establishment Labs in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Establishment Labs.

Establishment Labs is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Establishment Labs.

Establishment Labs Holdings Inc (NASDAQ:ESTA) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.01. Establishment Labs had a negative return on equity of 77.07% and a negative net margin of 56.74%.
View Establishment Labs' earnings history.

Establishment Labs updated its third quarter 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $18-21 million, compared to the consensus revenue estimate of $17.18 million.

3 brokers have issued 12 month price objectives for Establishment Labs' shares. Their forecasts range from $20.00 to $33.00. On average, they anticipate Establishment Labs' stock price to reach $25.33 in the next year. This suggests a possible upside of 42.3% from the stock's current price.
View analysts' price targets for Establishment Labs.

News coverage about ESTA stock has trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Establishment Labs earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Establishment Labs.

Establishment Labs saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 684,700 shares, an increase of 26.1% from the March 31st total of 543,000 shares. Based on an average trading volume of 153,900 shares, the short-interest ratio is currently 4.4 days.
View Establishment Labs' Short Interest.

Some companies that are related to Establishment Labs include Avanos Medical (AVNS), Inogen (INGN), Invacare (IVC), RTI Surgical (RTIX), Sientra (SIEN), Lakeland Industries (LAKE), Histogenics (HSGX), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Ocugen (OCGN), Allied Healthcare Products (AHPI), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), Bionik Laboratories (BNKL) and NanoVibronix (NAOV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Establishment Labs investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Sientra (SIEN), Allergan (AGN), BCE (BCE), Canadian Imperial Bank of Commerce (CM), Conduent (CNDT), Canadian Natural Resources (CNQ), Chevron (CVX) and Evolus (EOLS).

(ESTA) raised $50 million in an IPO on Thursday, July 19th 2018. The company issued 3,100,000 shares at $15.00-$17.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and BTIG was co-manager.

Establishment Labs trades on the NASDAQ under the ticker symbol "ESTA."

Establishment Labs' stock is owned by a variety of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (8.16%), Balyasny Asset Management LLC (0.64%), BigSur Wealth Management LLC (0.63%), CWM LLC (0.53%), Marshall Wace LLP (0.53%) and California Public Employees Retirement System (0.19%). Company insiders that own Establishment Labs stock include David L Bonvenuto, Jw Asset Management, Llc, Mezerville Roberto De and Nicholas Sheridan Lewin.
View institutional ownership trends for Establishment Labs.

ESTA stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, BigSur Wealth Management LLC, Marshall Wace LLP, MV Capital Management Inc., and Trexquant Investment LP.
View insider buying and selling activity for Establishment Labs.

ESTA stock was purchased by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, CWM LLC, California Public Employees Retirement System, Cambridge Investment Research Advisors Inc., and Globeflex Capital L P. Company insiders that have bought Establishment Labs stock in the last two years include David L Bonvenuto, Jw Asset Management, Llc, Mezerville Roberto De, and Nicholas Sheridan Lewin.
View insider buying and selling activity for Establishment Labs.

Shares of ESTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ESTA stock can currently be purchased for approximately $17.80.

Establishment Labs has a market capitalization of $415.93 million and generates $89.57 million in revenue each year. The company earns $-38,150,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Establishment Labs employs 505 workers across the globe.

The official website for Establishment Labs is www.establishmentlabs.com.

Establishment Labs' mailing address is Building B15 and 25 Coyol Free Zone, Alajuela G2, . The company can be reached via phone at 506 2434 2400 or via email at [email protected]